Patient and consumer reps on FDA advisory committees are supposed to represent the public, but do they?
In our new paper in @Health_Affairs Scholar (link in comments), we IDed the orgs that patient and consumer reps were actively involved with and tracked down pharma donors:
Wiliam Nordhaus was one of the greats - and an incredibly good, kind, humble, and generous person, with the highest standards. Let's mourn, and let's also celebrate him.
https://t.co/WJAB50QjQM
If you believe that mindless AI evaluations are legitimate then why would you spread the evaluation of Saez & @gabriel_zucman without first subjecting it to its own mindless AI evaluation?
I just did and it turns out the critic's errors all go in one direction.
Who’s influencing the voices meant to represent patients?
A new study led by USC Price Associate Professor and @USCSchaeffer Senior Scholar Genevieve Kanter (@ProfGenKanter) examines an overlooked source of potential industry influence: patient and consumer representatives on FDA advisory committees who have ties to pharmaceutical-funded advocacy organizations.
These committees help inform FDA decisions about new drugs and medical devices, making transparency around those relationships a matter of public health and public trust.
Read the full article to see how USC Price research is raising questions about disclosure policies and accountability in federal decision-making.
Read Here: https://t.co/LbiwLMTff8
Kanter study finds 38% of FDA advisory committees 2013-22 had a patient or consumer representative tied to a pharma-funded advocacy organization
https://t.co/ULXjYmBdVl
@woongworks@statnews great thought. wish we could evaluate this but there is only 1 patient rep per mtg so we can't compare 2 reps (1 w/ industry PAO tie vs 1 w/o). we are working on a paper that looks at whether pt reps vote differently from the rest of the panel, which may get at some of this
Patient and consumer reps on FDA advisory committees are supposed to represent the public, but do they?
In our new paper in @Health_Affairs Scholar (link in comments), we IDed the orgs that patient and consumer reps were actively involved with and tracked down pharma donors:
I think this is a hugely important point about the clinical trial prediction market concept.
However, my personal 2c: rather than depress trial enrollment, I think this could be misused to falsely drive trial enrollment (by driving up price to imply insiders believe drug works)
Betting markets for drug approvals and clinical trials are here. But what exactly are these markets and how do they work? Why would we want them? What can go wrong?
In my commentary in JAMA Health Forum, I answer these questions and provide an explainer
https://t.co/GolkunLXMB
In which Big Brained economist and cancer patient Chalres Manski identifies* the distorting incentives in cancer care and drug development... I love stories that combine economics, economists, and health policy
*yeah, a bit of inside-baseball there
https://t.co/5gYMKFJ77v
Every college syllabus should include these graphs.
Use AI for homework, you will get it done faster and get a higher grade, and then get crushed on the exam.
A prolonged vacancy atop the FDA could mean delayed work on new treatments until there's greater policy clarity, USC Schaeffer's @ProfGenKanter tells @PharmaVoice.
https://t.co/qqn96CutUC
Long Post: What’s going on with these so-called Complete Response Letters (CRLs)?
There’s long been strong public and investor interest in CRLs, the letters the FDA issues to companies explaining exactly why a drug application (deficiencies in safety, efficacy, manufacturing, ...).
FDA launched a major “radical transparency” push in 2025 under then-Commissioner Marty Makary. In July 2025 the agency released more than 200 CRLs, mostly for previously approved applications. In September 2025 it announced real-time or prompt public release of newly issued CRLs (including for pending or withdrawn or unapproved applications) and released another batch of 89. Some real-time style releases followed before the later pause.
Industry pushback followed, including a citizen petition filed on April 20, 2026 (by Covington & Burling on behalf of an unnamed pharmaceutical company). The petition raised concerns about process, redactions, and legal authority for disclosing CRLs tied to unapproved applications.
FDA reportedly paused new real-time releases around April 2026. An HHS spokesperson later confirmed the temporary pause while the agency evaluates next steps.
The agency is now moving to formalize and expand the policy through rulemaking under RIN 0910-AJ16 (“Proactive Disclosure of Complete Response Letters”).
On the roughly 9–18 month timeframe: This is a realistic ballpark based on how federal rulemaking usually works. From an NPRM (expected October 2026) you typically get a public comment period (often 30–60 days), agency review of comments, internal clearances (including OIRA review for significant rules), and final publication. Many rules take 6–12+ months from proposal to final rule, and complex or contested ones can stretch longer, sometimes well over a year. That’s standard across agencies and described in guides such as the Federal Register’s overview of the rulemaking process.
Key links:
Proposed rule (Unified Agenda): https://t.co/gLRKpc2MnQ
Citizen petition (April 20, 2026): https://t.co/M2jtPuuekN
openFDA CRL database: https://t.co/FDHyllSOWF
This is what I have gathered so far from public sources and reporting. It is not an exhaustive deep dive. Things can move or change once the NPRM is published in October.
RIP Ned Phelps
Ned Phelps followed his own intellectual journey.
When Keynesians relied on a long-run tradeoff between unemployment and inflation, he showed why this was a weak reed to stand on. Thus was born the natural rate hypothesis (although the coining of the word goes to Friedman, a year after Ned’s paper).
When, later, New Keynesians were focusing on nominal rigidities, he built models of fluctuations where nominal rigidities played no role. When New Classicals were exploring the cyclical implications of competitive markets, he focused on the role of distortions in goods and labor markets, be it efficiency wages, or variable markups.
It would be fair to say that, today, the frontier macro models embody the natural rate hypothesis, and many of the distortions Ned focus on---and, what he did not like, i.e. nominal rigidities.
His style was highly idiosyncratic. He was often a poor expositor of his fundamental insights. He did not listen much to others, pursuing his agenda with focus and passion. But, to use an overused but appropriate expression, he was certainly one of the giants in the field. We often met and sometimes fought, be it on hysteresis or nominal rigidities, but I had infinite respect for him.
Hello! Thank you for asking. The issue you raise is more a work permit issue than a physical location issue. Unfortunately we won't be able to sponsor a US work visa at this time, so the candidate would need to be able to have permission to work in the US. Within the US, the RA can work remotely.
SCOOP: FDA Commissioner Marty Makary is resigning from the agency.
Kyle Diamantas, who previously worked as the top food official at the agency, will lead the FDA in an acting capacity.
w/ @Gardner_LM: https://t.co/k4ORTbX8tj